• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-A12B/A filed by Vanda Pharmaceuticals Inc.

    8/8/24 7:47:27 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    8-A12B/A 1 d860707d8a12ba.htm 8-A12B/A 8-A12B/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-A/A

    (Amendment No. 2)

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Vanda Pharmaceuticals Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   03-0491827

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    2200 Pennsylvania Avenue NW

    Suite 300E

    Washington, DC

      20037
    (Address of principal executive offices)   (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    to be registered

     

    Name of each exchange on which

    each class is to be registered

    Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share   The Nasdaq Global Market

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

    Securities Act registration statement or Regulation A offering statement file number to which this form relates:

    001-34186

    Securities to be registered pursuant to Section 12(g) of the Act:

    None.

     

     

     


    Explanatory Note

    This Amendment No. 2 on Form 8-A/A is being filed by the registrant for the purpose of amending and supplementing the description of the registrant’s securities contained in the Form 8-A filed by the registrant with the Securities and Exchange Commission (the “SEC”) on April 17, 2024, as amended by the Form 8-A/A filed by the registrant with the SEC on May 3, 2024.

    Item 1. Description of Registrant’s Securities to be Registered.

    On August 7, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 2 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024, as amended by that certain Amendment No. 1 to the Rights Agreement, dated as of May 3, 2024 (“Amendment No. 1”), in each case by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent (as amended, the “Rights Agreement”).

    The Amendment (i) made certain punctuation corrections to the definition of “Acquiring Person” and (ii) amended and restated the definitions of “Acting in Concert” and “Beneficial Owner” to make certain clarifying changes. Copies of the original Rights Agreement and Amendment No. 1 were filed with the SEC on the Company’s Current Reports on Form 8-K as Exhibits 4.1 on April 17, 2024 and May 3, 2024, respectively.

    The foregoing summary description of the terms of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, which is attached hereto as Exhibit 4.3 and is incorporated herein by reference.


    Item 2. Exhibits.

     

    Exhibit No.   

    Description

    3.1    Amended and Restated Certificate of Designation of Rights, Preferences and Privileges of Series A Junior Participating Preferred Stock of Vanda Pharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).
    4.1    Rights Agreement, dated as of April  17, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC as rights agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on April 17, 2024).
    4.2    Amendment No. 1 to the Rights Agreement, dated as of May  3, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC, as rights agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on May 3, 2024).
    4.3    Amendment No. 2 to the Rights Agreement, dated as of August  7, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC, as rights agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 8, 2024).


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

    Date: August 8, 2024     VANDA PHARMACEUTICALS INC.
        By:  

    /s/ Timothy Williams

       

    Name:  Timothy Williams

       

    Title:   Senior Vice President, General Counsel and Secretary

    Get the next $VNDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    11/5/2025$11.00Buy
    B. Riley Securities
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

    WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form. This letter stems from CDER's agreed re-review of the jet lag application under the October 1 collaborative framework agreement. The FDA acknowledged positive efficacy from V

    1/8/26 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

    WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic response that affects a substantial portion of the population and has long been recognized as a factor affecting military operational readiness.

    12/30/25 6:13:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/21/25 9:23:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    5/19/25 5:13:38 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/16/25 9:10:04 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    6/9/25 5:36:16 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

    H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    10/31/24 6:31:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

    7/11/24 7:49:37 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vanda Pharmaceuticals Inc.

    SCHEDULE 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    1/9/26 4:23:37 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    1/8/26 7:09:31 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    12/30/25 6:45:43 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    View All

    Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

    WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

    3/17/23 7:00:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in Q4 2025Vanda announced collaborative framework with the FDA for resolution of certain disputesRe-review of Vanda's sNDA for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today an

    10/29/25 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 5:16:07 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/13/24 10:53:14 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    2/9/24 9:59:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care